Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 5:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–47 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Fluocinolone Clear all
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT02260986
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Placebo (for Dupilumab), Topical Corticosteroid (TCS)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
50
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Sep 23, 2026, 5:16 AM EDT
Completed Early Phase 1 Interventional

Fluocinolone Acetonide Implant for Retinal Vein Occlusion (RVO)

NCT00636493
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
fluocinolone acetonide (Retisert Implant)
Device
Lead sponsor
Glenn Jaffe
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Sep 23, 2026, 5:16 AM EDT
Completed Not applicable Interventional Results available

A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion

NCT00952614
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
fluocinolone acetonide (Retisert Implant, Bausch and Lomb)
Device
Lead sponsor
Glenn Jaffe
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Sep 23, 2026, 5:16 AM EDT
Completed No phase listed Observational

Cutaneous Lupus Medication Experience Study

NCT02176148
View directory record Official record
Conditions
Cutaneous Lupus
Interventions
fluocinonide 0.05% cream
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
12 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Sep 23, 2026, 5:16 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma

NCT00472966
View directory record Official record
Conditions
Melasma
Interventions
Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 23, 2026, 5:16 AM EDT
Recruiting Phase 3 Interventional

The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment

NCT05486468
View directory record Official record
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate
Interventions
Yutiq 0.18 MG Drug Implant, Sham Injection
Drug · Other
Lead sponsor
Texas Retina Associates
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 23, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis

NCT01469767
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Fluocinonide cream
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 23, 2026, 5:16 AM EDT
Terminated Phase 2 Interventional Results available

Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina

NCT00770770
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
3
States / cities
Lexington, Kentucky • Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Sep 23, 2026, 5:16 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Steroids for Early Treatment of Radiation Retinopathy

NCT03238157
View directory record Official record
Conditions
Radiation Retinopathy
Interventions
Fluocinolone Acetonide (FA) implant
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Sep 23, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy

NCT01422408
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Fluocinonide Cream, Management of Therapy Complications, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Sep 23, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis

NCT02748512
View directory record Official record
Conditions
Non-Infectious Uveitis
Interventions
FAI Insert administered using the Mk II inserter, FAI Insert administered using the Mk I inserter
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Colorado Springs, Colorado • Waltham, Massachusetts • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Sep 23, 2026, 5:16 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert

NCT05070728
View directory record Official record
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Intermediate
Interventions
Sham Injector, FAI Insert
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Sep 23, 2026, 5:16 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03568318
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, Upadacitinib, Topical corticosteroids (TCS)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 75 Years
Enrollment
1,533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
59
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 23, 2026, 5:16 AM EDT
Completed Phase 4 Interventional Results available

Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment

NCT00543296
View directory record Official record
Conditions
Uveitis
Interventions
0.59 mg Fluocinolone Acetonide implant
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Sep 23, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study

NCT01304706
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Alpharetta, Georgia
Source: ClinicalTrials.gov public record
Updated May 3, 2015 · Synced Sep 23, 2026, 5:16 AM EDT
Recruiting Phase 4 Interventional

Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study

NCT04207931
View directory record Official record
Conditions
Central Centrifugal Cicatricial Alopecia (CCCA)
Interventions
Topical steroid class I-II, Triamcinolone Acetonide, Doxycyline, Minoxidil
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 23, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert

NCT01694186
View directory record Official record
Conditions
Non-Infectious Uveitis
Interventions
FAI insert, Sham injection
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
16
States / cities
Beverly Hills, California • Sacramento, California • Torrance, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Sep 23, 2026, 5:16 AM EDT
Active, not recruiting Early Phase 1 Interventional

A Study of Yutiq Steroid Insert During Glaucoma Tube Implant Surgery

NCT04918121
View directory record Official record
Conditions
Glaucoma
Interventions
Yutiq 0.18 MG Drug Implant
Drug
Lead sponsor
Sanjay Asrani
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 23, 2026, 5:16 AM EDT
Terminated Phase 2 Interventional Results available

Sorafenib-induced Hand- Foot Skin Reaction Treatment

NCT00667589
View directory record Official record
Conditions
Hand-foot Skin Reaction, Rash
Interventions
urea 40% cream, fluocinonide 0.05% cream, tazarotene 0.1% cream, bland emollient cream (Udderly smooth® Udder Cream)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Sep 23, 2026, 5:16 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants

NCT00407082
View directory record Official record
Conditions
Noninfectious Posterior Uveitis
Interventions
fluocinolone acetonide intravitreal implant, Fluocinolone acetonide 2.1mg
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
6 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Sep 23, 2026, 5:16 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Using an Internet Study to Improve Adherence for Psoriasis Patients

NCT01802580
View directory record Official record
Conditions
Psoriasis
Interventions
Internet Survey, fluocinonide 0.05% ointment
Behavioral · Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Sep 23, 2026, 5:16 AM EDT
Completed Phase 4 Interventional Results available

VANOS Cream and Skin Barrier Function

NCT00819507
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Fluocinonide
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
12 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 23, 2026, 5:16 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Neo-Synalar Modified 48 Hour Patch Test

NCT02168478
View directory record Official record
Conditions
Allergy
Interventions
Neo-Synalar Cream, Sodium Lauryl Sulfate Aqueous Solution (0.40%), Saline
Drug · Other
Lead sponsor
Noah Rosenberg, MD
Industry
Eligibility
18 Years to 79 Years
Enrollment
206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Sep 23, 2026, 5:16 AM EDT